IOL Chemicals and Pharmaceuticals Limited (IOLCP), one of the largest producers of organic chemicals and bulk drugs in India, has announced that it has received DMF Registration No. 2009-179 from Health Canada, the drug regulatory body of Canada for exporting its most successful pharmaceutical product, the anti-inflammatory drug Ibuprofen, to the country. IOLCP is expected to get the formal approval from Health Canada and also from USFDA. EDQM and many European countries during the next couple of months for exporting Ibuprofen to these countries. IOLCP has plans to launch its anti-inflammatory drug Ibuprofen in over 15 countries under its own brand name and has received approvals from the authorities of Japan, Iran and Geneva for the export of Ibuprofen and would soon start exporting it to these countries.
Mr. Vijay Singla, President Drugs, IOL Chemicals and Pharmaceuticals Limited, said, “We expect the next fiscal to be extremely exciting for us as we start exporting to newer markets with ready demand and ample of opportunities. We are aiming total sales of Rs.600 crore with 30 % to 40% of contribution from our exports revenue in the year 2010-11. The lucrative markets of Canada, US and Europe offer immense potential for the export of Ibuprofen as active pharmaceuticals ingredient (API). We foresee export potential of about 2,000 TPA and 600 TPA in Canada and Australia respectively. We are confident our commitment to the quality of our products will enable us to achieve our targeted growth.”
IOLCP has received DMF registration no. for Ibuprofen from United States Food & Drug Administration (USFDA) and registered Certificate of Suitability to EDQM (European Directorate for the Quality of Medicines & HealthCare) to export Ibuprofen to the USA and European countries. IOLCP also aims to tap new export markets such as France, Russia, Korea and Taiwan for Ibuprofen and is already exporting its various products to over 52 countries across the world including Argentina, Brazil, China, Denmark, Germany, Singapore, Hong Kong, Kenya, Malaysia, Peru, Egypt etc.
IOLCP is taking big strides in its endeavour to raise its exports revenue and had recently received many coveted certifications for exports of its pharma product, Ibuprofen, to various countries. These certifications include Accreditation Certificate of Foreign Drug Manufacture from Ministry of Health, Labor and Welfare, Japan, and Certificate of Pharmaceutical Product (COPP) from Director, Health & Family Welfare, Punjab conforming to the WHO guidelines, which certifies IOLCP’s Ibuprofen as an Active Pharmaceuticals Ingredient (API) fit to be exported to other countries from India.
IOLCP’s products also have received coveted Kosher Certification from the Kosher Inspection Service India, which confirms that no animal fats or meat bones are used in the processing of its various products. The certification will enhance the acceptance of IOLCP’s various products in the European countries and Israel leading to strengthened revenue from exports for the company. The Kosher Certification to IOLCP applies to its following products - Ibuprofen, Glacial Acetic Acid/Acetic Acid, Ethyl Acetate, Acetic Anhydride, Poly Aluminium Chloride (PAC), Green Acid/Spent Acid, Monochloro Acetic Acid (MCA), Acetyl Chloride and Isobutyl Benzene (IBB).
IOLCP was also recently accorded the coveted status of Star Export House in accordance with the provisions of the Foreign Trade Policy, 2004-2009 by the Ministry of Commerce and Industry, Department of Commerce, Government of India, which makes the company eligible for many privileges that will help enhance its business and exports revenues.
The production capacity of Ibuprofen has been the stronghold of IOLCP's pharmaceutical operations and the company has recently boosted its Ibuprofen plant capacity to 3600 TPA from 1800 TPA. The company further aims to expand the capacity to 6000 TPA. IOLCP's expansion plans worth Rs.256 crore include capacity expansion for its various product lines, forward and backward integration and increase in cogeneration of power.
More From This Section
As part of its Backward Integration plan, the company is going to commence a new plant of Isobutyl Benzene (IBB) having annual capacity of 6600 MT to ensure ready availability of the most important raw material of Ibuprofen. The production in this plant is expected to commence in next quarter.
“We are working at an enormous pace to increase our manufacturing capacity to keep up with the burgeoning demand of our most successful pharmaceutical product, ibuprofen, which is used to reduce fever and treat pain or inflammation caused by many ailments such as headache, toothache, back pain, arthritis, menstrual cramps, or minor injuries,” added Mr. Singla.
As part of its Backward and forward Integration plan, IOLCP will add three more products i.e. Mono Chloro Acetic Acid(MCA) with a capacity of 7200 TPA and Acetyl Chloride with a capacity of 5200 TPA, ad Iso-Butyl Benzene (IBB) with the capacity of 6600 TPA using Acetic Acid and Acetic Anhydride as a raw material.
IOLCP also plans to increase the production capacity of Acetic Acid from 50000 TPA to 75000 TPA, Ethyl Acetate from 33000 TPA to 36000 TPA and that of Acetic Anhydride from 12000 TPA to 18000 TPA.
IOLCP has recently been once again awarded the most prestigious National Energy Conservation Award 2008 (second prize in chemical sector) for its ongoing efforts towards new technology implementation to conserve precious energy resources. The company won this award consecutively for the previous three years—2005, 2006 and 2007, as well.
Apart from the facts that IOLCP currently co-generates around 4 MW of power which is being upgraded to 17 MW and its energy conservation initiatives, IOLCP is also actively involved in protection and preservation of the environment in and around its manufacturing units. The company's environmental policy includes sustained efforts towards minimizing adverse environmental impact by controlling emission, effluents and waste generation at its manufacturing units in order to prevent pollution and reduce its carbon footprint.
At IOLCP, there is constant quest for Innovation in products and processes. Driven by an intensive R&D program manned by a highly trained and competent team, this drive for innovation has led the company to develop and enhance its capabilities over the years. Equipped with cutting edge tools and facilities, IOLCP's research and development process is managed by a highly trained and motivated team of experts. IOLCP's vast capabilities in research and breakthrough developments have allowed the company to undertake in-house development of technologies required in its manufacturing process.
About IOL Chemicals and Pharmaceuticals Limited
Established in 1986, IOLCP, a public-listed company (BSE), is one of the largest manufacturers of industrial chemicals and bulk drugs with presence in over 52 countries across the world. IOLCP manufactures and supplies Industrial Chemicals and Bulk Drugs for use in various pharmaceutical, Textile, Packaging, Lamination, Pesticides, Food processing applications. Its product portfolio includes industrial organic chemicals such as acetic acid, glacial acetic acid, ethyl acetate, acetic anhydride and bulk drugs like ibuprofen. IOLCP is currently in a phase of expansion with an investment outlay of Rs. 256 crore which would include capacity expansion for its various product lines, forward and backward integration and increase in cogeneration of power. IOLCP's overseas customers are spread out across several countries including Argentina, Brazil, China, Denmark, Germany, Singapore, Hong Kong, Kenya, Malaysia, Peru, Egypt and many others. The company has strong business relationships with a number of prestigious clients such as Ranbaxy Labs, Dr Reddy, DS Group, CIPLA, Uflex Industries, ITC Limited, ICI Paints, Asian Paints, Pidilite, Rallis India, Hindustan Polymide, Gujarat Super Phosphate, and Avon Organics Ltd. etc. For more information on IOLCP, please visit http://www.iolcp.com